AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Disease-control rate (stable disease for ≥ 6 months or partial or complete response)
Number of subjects: 145
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Progression-free survival (PFS)
Number of subjects: 145
Study 34607609 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival (OS)
Number of subjects: 145
Study 34607697 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clascoterone
Number of subjects: 0
Study 34607697 — intervention group
Group type: COMPARATOR
Intervention: Current medications (not specified)
Number of subjects: 0
Study 34607873 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy with vaginal vault suspension
Number of subjects: 321
Study 34607873 — intervention group
Group type: COMPARATOR
Intervention: Uterine preservation surgical group
Number of subjects: 321
Study 34607899 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL-based ACT with checkpoint inhibitors (Ipilimumab 3 mg/kg prior to tumor resection and Nivolumab 3 mg/kg every 2 weeks for 4 doses)
Number of subjects: 25
Study 34607899 — intervention group
Group type: EXPERIMENTAL
Intervention: TIL-based ACT with checkpoint inhibitors
Number of subjects: 25
Study 34608030 — intervention group
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Number of subjects: 4
Study 34608049 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver mastery
Number of subjects: 41
Study 34608049 — intervention group
Group type: COMPARATOR
Intervention: Known clinical predictors (patient age, Karnofsky Performance Status, type of surgery, O6-methylguanine-DNA-methyltransferase promotor methylation status)
Number of subjects: 41
Study 34608049 — intervention group
Group type: COMPARATOR
Intervention: Model with known clinical predictors
Number of subjects: 41
Study 34608049 — intervention group
Group type: EXPERIMENTAL
Intervention: Model with caregiver mastery
Number of subjects: 41
Study 34608577 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG amplitude values during stair climbing in children with DMD
Number of subjects: 32
Study 34608577 — intervention group
Group type: COMPARATOR
Intervention: sEMG amplitude values during stair climbing in children with DMD (levels II-III)
Number of subjects: 32
Study 34608577 — intervention group
Group type: EXPERIMENTAL
Intervention: sEMG amplitude values and physical performance assessments
Number of subjects: 32
Study 34608631 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod 10 mg/kg
Number of subjects: 34
Study 34608631 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod 25 mg/kg
Number of subjects: 34
Study 34608859 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular advancement device (MAD) treatment
Number of subjects: 100
Study 34608859 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders to MAD treatment
Number of subjects: 100
Study 34608859 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonresponders to MAD treatment
Number of subjects: 100
Study 34609196 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep Learning model for triaging MRI examinations
Number of subjects: 4581
Study 34609195 — intervention group
Group type: EXPERIMENTAL
Intervention: CT abnormalities at 3-month follow-up
Number of subjects: 80
Study 34609195 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat imaging at 1-year follow-up
Number of subjects: 80
Study 34609195 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent breathlessness
Number of subjects: 80
Study 34609195 — intervention group
Group type: EXPERIMENTAL
Intervention: Cough
Number of subjects: 80
Study 34609622 — intervention group
Group type: EXPERIMENTAL
Intervention: FA Score based on selected fatty acids (myristic, petroselinic, α-linolenic, arachidonic)
Number of subjects: 462
Study 34609622 — intervention group
Group type: EXPERIMENTAL
Intervention: FA Score
Number of subjects: 462
Study 34609691 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a single 25-Gy dose
Number of subjects: 8
Study 34609691 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT)
Number of subjects: 8
Study 34609964 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled human malaria infection (CHMI) with a clone of Plasmodium vivax from Thailand by mosquito-bite CHMI
Number of subjects: 8
Study 34609964 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood-stage CHMI with PvW1 parasite stabilate at 3 different dilutions
Number of subjects: 8
Study 34609964 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic analysis of PvW1 parasite DNA
Number of subjects: 8
Study 34610114 — intervention group
Group type: EXPERIMENTAL
Intervention: PWH with COPD
Number of subjects: 4
Study 34610114 — intervention group
Group type: EXPERIMENTAL
Intervention: PWH without COPD
Number of subjects: 4
Study 34610114 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 4
Study 34610607 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylene blue (1.5 mg kg-1 intravenously)
Number of subjects: 25
Study 34610756 — intervention group
Group type: EXPERIMENTAL
Intervention: Anlotinib, dosage and duration not specified
Number of subjects: 0
Study 34610763 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe SVD burden
Number of subjects: 623
Study 34610808 — intervention group
Group type: EXPERIMENTAL
Intervention: Adherence to WHO handwashing guidelines
Number of subjects: 6064
Study 34610808 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent cases of COVID-19 morbidity
Number of subjects: 6064
Study 34610808 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent cases of COVID-19 mortality
Number of subjects: 6064
Study 34610874 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES)
Number of subjects: 6647
Study 34610874 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 6647
Study 34610874 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients with left main involvement
Number of subjects: 6647
Study 34610874 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) in patients with left main involvement
Number of subjects: 6647
Study 34610874 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with second-generation drug-eluting stents (DES) in patients without left main involvement
Number of subjects: 6647
Study 34610874 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG) in patients without left main involvement
Number of subjects: 6647
Study 34610923 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydrotestosterone (median 0.9 nmol/L)
Number of subjects: 243
Study 34610923 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (median 12.1 nmol/L)
Number of subjects: 243
Study 34610923 — intervention group
Group type: COMPARATOR
Intervention: Control group (lowest tertile of dihydrotestosterone)
Number of subjects: 243
Study 34610927 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia with a standardised anaesthetic protocol for IOP measurement
Number of subjects: 100
Study 34610927 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia for other reasons (Control)
Number of subjects: 100
Study 34611045 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy (APT), including aspirin and other antiplatelet drugs, administered to 730 patients (9% of total), with 680 receiving single APT and 50 receiving dual APT.
Number of subjects: 7824
Study 34611164 — intervention group
Group type: EXPERIMENTAL
Intervention: Afucosylated PfEMP1-specific IgG
Number of subjects: 0
Study 34611164 — intervention group
Group type: COMPARATOR
Intervention: Subunit PfEMP1 (VAR2CSA) vaccine
Number of subjects: 0
Study 34611424 — intervention group
Group type: EXPERIMENTAL
Intervention: D-CTAG regimen (decitabine, cytarabine, aclarubicin) with rhTPO and G-CSF
Number of subjects: 0
Study 34611902 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent very low calorie diet (VLCD) with full meal replacement and intensive dietitian support
Number of subjects: 619
Study 34611902 — intervention group
Group type: COMPARATOR
Intervention: Interventions aimed at increasing acceptance of weight gain
Number of subjects: 619
Study 34612019 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 3837
Study 34612058 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-19b-3p
Number of subjects: 564
Study 34612058 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline level of miR-19b-3p
Number of subjects: 564
Study 34612058 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of miR-19b-3p level
Number of subjects: 564
Study 34612495 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation preconception plus during pregnancy
Number of subjects: 1035
Study 34612495 — intervention group
Group type: COMPARATOR
Intervention: Multivitamin supplementation during pregnancy only
Number of subjects: 1035
Study 34613416 — intervention group
Group type: EXPERIMENTAL
Intervention: Telavancin 5 mg/kg IV administered 3 hours before haemodialysis
Number of subjects: 8
Study 34613416 — intervention group
Group type: COMPARATOR
Intervention: Telavancin 5 mg/kg IV administered post-haemodialysis
Number of subjects: 8
Study 34613570 — intervention group
Group type: EXPERIMENTAL
Intervention: OBP-801 (1.0 mg/m²)
Number of subjects: 3
Study 34613570 — intervention group
Group type: EXPERIMENTAL
Intervention: OBP-801 (2.0 mg/m²)
Number of subjects: 3
Study 34613570 — intervention group
Group type: EXPERIMENTAL
Intervention: OBP-801 (3.0 mg/m²)
Number of subjects: 3
Study 34614208 — intervention group
Group type: EXPERIMENTAL
Intervention: tofacitinib
Number of subjects: 0
Study 34614506 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax (200-400 mg daily starting day -8 for 6-7 doses) plus fludarabine (30 mg/m2 per day for 4 doses) and busulfan (0.8 mg/kg twice daily for 8 doses on day -5 to day -2)
Number of subjects: 22
Study 34614506 — intervention group
Group type: COMPARATOR
Intervention: Standard FluBu2 (fludarabine and busulfan)
Number of subjects: 22
Study 34615429 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic load (GL)
Number of subjects: 135
Study 34615429 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycemic index (GI)
Number of subjects: 135
Study 34615429 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted dietary inflammatory index (ADII)
Number of subjects: 135
Study 34615458 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri drops
Number of subjects: 28
Study 34615458 — intervention group
Group type: COMPARATOR
Intervention: Placebo drops without probiotics
Number of subjects: 28
Study 34615668 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with COVID-19 (n=52)
Number of subjects: 52
Study 34615705 — intervention group
Group type: EXPERIMENTAL
Intervention: Human MAIT cells after allogeneic hematopoietic stem cell transplantation
Number of subjects: 0
Study 34615705 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro signals from allogeneic cells and cytokines
Number of subjects: 0
Study 34615705 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo model of T-cell-mediated xenogeneic graft-versus-host disease in immunodeficient mice
Number of subjects: 0
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148 monotherapy (0.1-1.6 mg/kg i.v. every 3 weeks)
Number of subjects: 126
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148 once-weekly monotherapy (0.4 or 0.6 mg/kg i.v.)
Number of subjects: 126
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148 + nivolumab every 3 weeks
Number of subjects: 126
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148
Number of subjects: 126
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148 + nivolumab
Number of subjects: 126
Study 34615718 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986148 ± nivolumab
Number of subjects: 126
Study 34615723 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib (100 mg) and Ibrutinib (560 mg)
Number of subjects: 37
Study 34615725 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivuxolimab (0.3 to 10 mg/kg)
Number of subjects: 31
Study 34615867 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous spinal stimulation
Number of subjects: 8
Study 34616296 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab as first-line treatment
Number of subjects: 468
Study 34616588 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Number of subjects: 0
Study 34616588 — intervention group
Group type: COMPARATOR
Intervention: Concurrent chemotherapy (cisplatin 25 mg/m2) and radiation therapy
Number of subjects: 0
Study 34616960 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal bundle of care implemented gradually during the study period (2018-2021)
Number of subjects: 0
Study 34616960 — intervention group
Group type: EXPERIMENTAL
Intervention: Colorectal bundle of care
Number of subjects: 0
Study 34616960 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of risk factors for SSIs
Number of subjects: 0
Study 34617591 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthcare intervention strategies to systematically identify familial hypercholesterolaemia
Number of subjects: 0
Study 34617591 — intervention group
Group type: COMPARATOR
Intervention: Usual care (incidental approaches)
Number of subjects: 0
Study 34617912 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable photoplethysmographic device (Senbiosys)
Number of subjects: 35
Study 34617915 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular motivational and assessment text messages
Number of subjects: 600
Study 34617915 — intervention group
Group type: COMPARATOR
Intervention: Assessment text messages only
Number of subjects: 600
Study 34618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 3-mg dose of PF-06881894
Number of subjects: 25
Study 34618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 6-mg dose of PF-06881894
Number of subjects: 25
Study 34618197 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple 6-mg doses of PF-06881894
Number of subjects: 25
Study 34618197 — intervention group
Group type: COMPARATOR
Intervention: PF-06881894 (3- or 6-mg doses)
Number of subjects: 25
Study 34618321 — intervention group
Group type: EXPERIMENTAL
Intervention: LumiraDx D-Dimer Test (POC)
Number of subjects: 1860
Study 34618345 — intervention group
Group type: EXPERIMENTAL
Intervention: REC-2282 (AR-42)
Number of subjects: 0
Study 34618347 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab
Number of subjects: 1427
Study 34618498 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital messaging intervention (0-6 messages daily for 6 months)
Number of subjects: 45
Study 34618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm thickening fraction (TF) >28%
Number of subjects: 74
Study 34618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragm excursion >25.4 mm
Number of subjects: 74
Study 34618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Left diaphragm thickening fraction (TF) >26.8%
Number of subjects: 74
Study 34618930 — intervention group
Group type: EXPERIMENTAL
Intervention: Left diaphragm excursion >21.5 mm
Number of subjects: 74
Study 34619098 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b2 (tozinameran, Pfizer-BioNTech) vaccine
Number of subjects: 3436957
Study 34619104 — intervention group
Group type: EXPERIMENTAL
Intervention: Benralizumab 30 mg (subcutaneous injection) every 4 weeks for three doses, then every 8 weeks thereafter.
Number of subjects: 598
Study 34619467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 138
Study 34619467 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 138
Study 34619467 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib (second-line treatment)
Number of subjects: 138
Study 34619467 — intervention group
Group type: COMPARATOR
Intervention: Everolimus (second-line treatment)
Number of subjects: 138
Study 34619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (≥10%)
Number of subjects: 103
Study 34619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (≥10%)
Number of subjects: 103
Study 34619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (muscle CSAs)
Number of subjects: 103
Study 34619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight gain (muscle CSAs)
Number of subjects: 103
Study 34619678 — intervention group
Group type: EXPERIMENTAL
Intervention: Knee function measures
Number of subjects: 103
Study 34619987 — intervention group
Group type: EXPERIMENTAL
Intervention: Decreased connectivity of the right basal forebrain to brain stem and basal ganglia
Number of subjects: 29
Study 34619987 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased connectivity of the arousal and attention network regions with the parietal, frontal, and temporal structures in the unaffected hemisphere
Number of subjects: 29
Study 34620022 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl-DL-leucine (ADLL) 3 g/day for 1 week followed by 5 g/day for 3 weeks to 1 year
Number of subjects: 6
Study 34620071 — intervention group
Group type: EXPERIMENTAL
Intervention: BAPST regimen (Benserazide, Apomorphine, Pantoprazole, Simvastatin, Trimetazidine)
Number of subjects: 0
Study 34620081 — intervention group
Group type: EXPERIMENTAL
Intervention: Gym Tonic (GT) programme (12 weeks, twice/week)
Number of subjects: 318
Study 34620081 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (12 weeks)
Number of subjects: 318
Study 34620167 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 160/9/4.8 μg per actuation, 2 actuations, radiolabeled with technetium-99-pertechnetate.
Number of subjects: 0
Study 34620167 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) 320/18/9.6 μg, radiolabeled.
Number of subjects: 0
Study 34620173 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive breastfeeding (IBF)
Number of subjects: 1010
Study 34620173 — intervention group
Group type: COMPARATOR
Intervention: Intensive formula feeding or mixed feeding (IFF/Mixed)
Number of subjects: 1010
Study 34620173 — intervention group
Group type: COMPARATOR
Intervention: Common clinical variables (fasting glucose, 2-h glucose)
Number of subjects: 1010
Study 34620205 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidimensional physiotherapy
Number of subjects: 70
Study 34620205 — intervention group
Group type: COMPARATOR
Intervention: Usual physiotherapy
Number of subjects: 70
Study 34620222 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive interventions in neighbourhood-built environment (BE) and amenities
Number of subjects: 0
Study 34620226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial cell sheets (COMET)
Number of subjects: 2
Study 34620226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultivated oral mucosal epithelial cell sheets (COMET) followed by corneal transplantation
Number of subjects: 2
Study 34620248 — intervention group
Group type: EXPERIMENTAL
Intervention: Universal social needs screening using a 10-item, low-literacy, English-Spanish screener on touchscreens.
Number of subjects: 4608
Study 34620248 — intervention group
Group type: EXPERIMENTAL
Intervention: Community service referrals generated by the screener.
Number of subjects: 4608
Study 34620248 — intervention group
Group type: EXPERIMENTAL
Intervention: Qualitative feedback from ED staff and patients regarding the screening process.
Number of subjects: 4608
Study 34620250 — intervention group
Group type: EXPERIMENTAL
Intervention: Multilevel intervention including mailed FIT outreach and patient navigation support to follow-up colonoscopy
Number of subjects: 4000
Study 34620250 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 4000
Study 34620328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) devices in supine position
Number of subjects: 160
Study 34620328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) devices in standing position
Number of subjects: 160
Study 34620328 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioelectrical impedance analysis (BIA) devices with retractable handle
Number of subjects: 160
Study 34620335 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral or oral nutrition (EEN/ON)
Number of subjects: 224
Study 34620359 — intervention group
Group type: EXPERIMENTAL
Intervention: NST intervention (after NST + group)
Number of subjects: 120
Study 34620359 — intervention group
Group type: COMPARATOR
Intervention: No NST intervention (after NST - group)
Number of subjects: 120
Study 34620359 — intervention group
Group type: EXPERIMENTAL
Intervention: NST intervention
Number of subjects: 120
Study 34620360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein Mediterranean-style diet
Number of subjects: 0
Study 34620360 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study 34620360 — intervention group
Group type: EXPERIMENTAL
Intervention: Both high-protein Mediterranean-style diet and resistance exercise
Number of subjects: 0
Study 34620360 — intervention group
Group type: COMPARATOR
Intervention: Standard cardiac rehabilitation (control group)
Number of subjects: 0
Study 34620360 — intervention group
Group type: EXPERIMENTAL
Intervention: Measures of body composition, grip strength, CVD risk, and dietary adherence
Number of subjects: 0
Study 34620556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue sodium content in muscle
Number of subjects: 52
Study 34620556 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue sodium content in skin
Number of subjects: 52
Study 34620653 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Glycaemic Index (LGI) diet
Number of subjects: 16
Study 34620653 — intervention group
Group type: COMPARATOR
Intervention: High Glycaemic Index (HGI) diet
Number of subjects: 16
Study 34620666 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic stewardship intervention (ASI) using a decision tool and educational materials.
Number of subjects: 680
Study 34620666 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (control group).
Number of subjects: 680